



**HAL**  
open science

## **Erybraedin C, a natural compound from the plant Bituminaria bituminosa, inhibits both the cleavage and religation activities of human topoisomerase I.**

Cinzia Tesauro, Paola Fiorani, Ilda d'Annessa, Giovanni Chillemi, Gino  
Turchi, Alessandro Desideri

### ► To cite this version:

Cinzia Tesauro, Paola Fiorani, Ilda d'Annessa, Giovanni Chillemi, Gino Turchi, et al.. Erybraedin C, a natural compound from the plant Bituminaria bituminosa, inhibits both the cleavage and religation activities of human topoisomerase I.. Biochemical Journal, 2010, 425 (3), pp.531-539. 10.1042/BJ20091127 . hal-00479237

**HAL Id: hal-00479237**

**<https://hal.science/hal-00479237>**

Submitted on 30 Apr 2010

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Erybraedin C, a natural compound from the plant *Bituminaria bituminosa*, inhibits both the cleavage and religation activities of human topoisomerase I.

by

Cinzia Tesauro<sup>¶</sup>, Paola Fiorani<sup>¶</sup>, Ilda D'Annessa<sup>§</sup>, Giovanni Chillemi<sup>§</sup>, Gino Turchi<sup>^</sup> and Alessandro Desideri<sup>¶\*</sup>.

<sup>¶</sup>*CNR National Research Council, INFN National Institute for the Physics of Matter, CNISM and Department of Biology, University of Rome Tor Vergata, Via Della Ricerca Scientifica, Rome 00133, Italy*, <sup>§</sup>*CASPUR Interuniversities Consortium for Supercomputing Applications, Via dei Tizii 6, Rome 00185, Italy*, <sup>^</sup>*CNR-IBF, Biochemistry and Mutagenesis in Somatic Cells Unit, Campus CNR, Via Moruzzi 1, Pisa 50124, Italy*.

\*To whom correspondence should be addressed:

Prof. Alessandro Desideri  
Department of Biology  
University of Rome Tor Vergata,  
Via della Ricerca Scientifica,  
Rome 00133, Italy  
E-mail: [desideri@uniroma2.it](mailto:desideri@uniroma2.it)

## KEYWORDS

Erybraedin C, human topoisomerase I, Molecular Docking, inhibition mechanism, pterocarpan, inhibitor.

## ABSTRACT

The interaction of human topoisomerase I and erybraedin C, a pterocarpan purified from the plant *Bituminaria bituminosa* that has been shown to have an antitumor activity, has been investigated through enzymatic activity assays and molecular docking procedures. Erybraedin C is able to inhibit both the cleavage and the religation steps of the enzyme reaction. In both cases, preincubation of the drug with the enzyme is required to have a complete inhibition. Molecular docking simulations indicate that, when interacting with the enzyme alone, the preferential drug binding site is localized in proximity of the active Tyr723 residue with one of the two prenilic groups close to the active site residues Arg488 and His632, essential for the catalytic reaction. When interacting with the cleavable complex erybraedin C interacts with both the enzyme and DNA in a way similar to what found for topotecan. This is the first example of a natural compound able to act on both the cleavage and religation reaction of human topoisomerase I.

## INTRODUCTION

DNA topoisomerases are key enzymes that modulate the topological state of DNA through the breaking and rejoining of DNA strands. There are two classes of topoisomerases (type I and type II), both characterized by a catalytic mechanism which involves a nucleophilic attack of a DNA phosphodiester bond by a tyrosil residue from the enzyme, but type I cleaves one DNA strand whilst type II cleaves both strands. These enzymes have been shown to be essential in nearly all processes of DNA metabolism such as replication, transcription, recombination and chromosomal segregation [1,2]. The human topoisomerase I enzyme (Top1) is composed of 765 amino acids and has four distinct domains: the NH<sub>2</sub>-terminal domain (1-214), the core domain (215-635), the linker domain (636-712) and the COOH-terminal domain (713-765) [3-5]. The three-dimensional structure of reconstituted N-terminal truncated version of human Top1 in complex with a 22 bp DNA molecule shows the enzyme organized in multiple domains which “clamp on” the DNA molecule [4]. The active site tyrosine (Tyr-723) starts the catalytic cycle of the enzyme through a nucleophilic attack on the DNA backbone, resulting in the breakage of one DNA strand with the enzyme covalently attached to the 3'-phosphate to form the cleavable complex. After changing the linking number a second nucleophilic attack, driven by the 5'-hydroxyl DNA end, restores an intact double stranded DNA, and the enzyme is released [5].

DNA topoisomerase IB can be inhibited by several compounds that act through different mechanisms such as prevention of DNA-topoisomerase binding, inhibition of DNA cleavage or stabilization of the cleavable complex. Inhibitors of Top1 are divided in two classes: poisons and catalytic inhibitors [6,7]. Poisons include clinically used drug, such as the derivatives of the natural compound camptothecin (CPT) that reversibly bind the covalent Top1-DNA complex slowing down the religation of the cleaved DNA strand, thus inducing cell death. In detail two water soluble CPT derivatives, topotecan and irinotecan, have been approved by the FDA for clinical use. Catalytic inhibitors act through inhibiting any other step of Top1 enzymatic cycle [8].

Natural antioxidant from plants such as pterocarpan, the second group of isoflavones, have currently been received interests because of their antimicrobial, antiviral and antitumoral activity [9]. The pterocarpan erybraedin C (ERYC) has been recently purified from the flower aerial parts of *Bituminaria bituminosa* and *Bituminaria morisiana* and it has been chemically characterized [10,11]. This drug contains a tetracyclic ring system derived from the basic isoflavonoid skeleton by an ether linkage between 4 and 2 and is characterized by the presence of two hydroxyl groups, located, respectively, on 7 and 4' position, and two prenyl groups ( $\gamma,\gamma$ -dimethylallyl) on 8 and 5' position (Figure 1). ERYC because of the presence and distribution of phenolic hydroxyl and prenyl substituents may exhibit a high chain-

breaking antioxidant potential [12,13]. In addition ERYC exhibits anticlastogenic activity against mytomicin and the radio-mimetic bleomycin [14]. ERYC induced apoptosis in two human adenocarcinoma cell lines (HT29 and LoVo) proficient and deficient in MMR, p53 and Bcl-2 with a pattern that has been proposed to proceed through topoisomerase II poisoning [9].

In this paper we have investigated for the first time the interaction of ERYC with Top1 enzyme demonstrating that the drug inhibits both the cleavage and the religation processes. Molecular Docking indicates that ERYC, when interacting with the enzyme alone, binds in proximity of the active site blocking the catalytic reactions but still permitting the binding of the DNA substrate. Docking of ERYC with the protein-DNA cleavable complex indicates that the drug intercalates the DNA bases in a way similar to what found for topotecan (TPT).

## EXPERIMENTAL

### Yeast Strains, Plasmids and Chemicals

Camptothecin (Sigma) and ERYC (kindly provided by G. Turchi) were dissolved in dimethyl sulfoxide (Me<sub>2</sub>SO) to a final concentration of 4 mg/ml and 4.5 mg/ml respectively and stored at -20°C. Anti-FLAG M2 affinity gel, FLAG peptide and M2 monoclonal antibody were purchased from Sigma. *Saccharomyces cerevisiae* strain EKY3 (ura3-52, his3Δ200, leu2Δ1, trp1Δ63, top1::TRP1, MATα) was previously described [15]. Plasmid YCpGAL1- wild type and the catalytically inactive mutant Tyr723Phe were described previously [16,17]. The epitope-tagged constructs YCpGAL1-e-wild type and the YCpGAL1-e-Tyr723Phe contain the N-terminal sequence FLAG: DYKDDDY (indicated with “e”), recognized by the M2 monoclonal antibody.

### Purification of DNA Topoisomerase I

EKY3 cells were transformed with YCpGAL1-e-wild type or YCpGAL1-e-Tyr723Phe, grown on SC-uracil plus 2% (w/v) dextrose and diluted 1:100 in SC-uracil plus 2% (v/v) raffinose. At an optical density A<sub>595</sub> of 1.0, the cells were induced with 2% (v/v) galactose for 6 h. Cells were then harvested by centrifugation, washed with cold water and resuspended in 2 ml buffer/g cells using a buffer containing 50 mM Tris, pH 7.4, 1 mM EDTA, 1 mM ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid, 10% (v/v) glycerol completed with protease inhibitors cocktail (Roche 1836153) and supplemented with 0.1 mg/ml sodium bisulfite and 0.8 mg/ml sodium fluoride. After addition of 0.5 volumes of 425-600 μm diameter glass beads the cells were disrupted by vortexing for 30 s alternating with 30 s on ice. The lysate was centrifuged and KCl final concentration 0.15 M was added to the sample prior to loading onto 2 ml ANTI-FLAG M2 Affinity Gel column equilibrated as described in the technical bulletin (Sigma). The column was washed with 20 column volumes of TBS (50 mM Tris HCl, 150 mM KCl, pH 7.4). Elution of FLAG-fusion topoisomerase I was performed by competition with five column volumes of a solution containing 100 μg/ml FLAG peptide in TBS. Fractions of 500 μl were collected and glycerol final concentration 40% (v/v) was added; all preparations were stored at -20°C. The fractions were resolved by SDS-polyacrylamide gel electrophoresis; protein concentration and integrity were measured through immunoblot assay, using the epitope-specific monoclonal antibody M2.

### DNA Topoisomerase I Activity *in vitro*

Top1 activity was assayed with a DNA relaxation assay. Top1 preparations were incubated in 30 μl reaction volume containing 0.5 μg of negatively supercoiled plasmid pBlueScript KSII(+)-DNA and reaction buffer [20 mM Tris HCl pH 7.5, 0.1 mM Na<sub>2</sub>EDTA, 10 mM MgCl<sub>2</sub>, 50 μg/ml acetylated bovine serum albumin (BSA),

150 mM KCl].

To assess the effects of ERYC or CPT on enzyme activity different concentrations of the compounds were added. All the assays have been carried out in presence of 150 mM KCl, since in its absence the enzyme does not relax the substrate. Reactions were stopped with a final concentration of 0.5% (v/v) SDS after 1 h at 37° C and electrophoresis of the samples was carried out in a 1% (w/v) agarose gel in TBE (96 mM Tris, 91 mM Boric Acid, 1.9 mM EDTA), 10 Volts/cm. Where indicated, enzyme and inhibitor were pre-incubated at 37 °C for 10 min, prior of the addition of the substrate. The mixture was then incubated at 37°C for 15 min. The stability of the inhibitory effect of ERYC was monitored after pre-incubating Top1 and inhibitor at 37 °C for 10 min, the inhibitor–Top1 mixture was then diluted in the reaction buffer, the DNA substrate was added and incubated at 37°C for 15 min.

### **Cleavage/Religation Equilibrium**

Oligonucleotide CL25 (5'-GAAAAAAGACTTAGAAAAATTTTTA-3') has been radiolabeled with [ $\gamma^{32}\text{P}$ ] ATP at its 5' end. The CP25 complementary strand (5'-TAAAAATTTTCTAAGTCTTTTTTC-3') was phosphorylated at its 5' end with unlabeled ATP. The two strands were annealed at a 2-fold molar excess of CP25 over CL25. A final concentration of 20 nM duplex CL25/CP25 was incubated with an excess of enzyme at 25°C in 20 mM Tris pH 7.5, 0.1 mM Na<sub>2</sub>EDTA, 10 mM MgCl<sub>2</sub>, 50 µg/ml acetylated BSA in the presence or absence of 50 µM CPT or 100 µM ERYC. After 30 min, the reaction was stopped by adding 0.5% SDS and digested with trypsin after ethanol precipitation. Reaction products were resolved in 16% (v/v) acrylamide - 7 M urea gels in TBE (48 mM Tris, 45.5 mM Boric Acid, 1 mM EDTA).

### **Kinetics of Cleavage Using Oligonucleotide Substrate**

Oligonucleotide substrates CL14 (5'-GAAAAAAGACTTAG-3') was radiolabeled with [ $\gamma^{32}\text{P}$ ] ATP at their 5' end. The CP25 complementary strand (5'-TAAAAATTTTCTAAGTCTTTTTTC-3') was phosphorylated at its 5' end with unlabeled ATP. CL14/CP25 was annealed as previously described. The suicide cleavage reactions were carried out by incubating 20 nM of the duplex with an excess of enzyme pre-incubated with DMSO or different concentrations of ERYC for 10 min, in 20 mM Tris pH 7.5, 0.1 mM Na<sub>2</sub>EDTA, 10 mM MgCl<sub>2</sub>, 50 µg/ml acetylated BSA, and 150 mM KCl at 23°C in a final volume of 50 µl as described by Yang and Champoux [18]. After 30 min 5 µl aliquots have been removed and the reaction stopped with 0.5% (w/v) SDS. After ethanol precipitation samples were resuspended in 5 µl of 1 mg/ml trypsin and incubated at 37°C for 30 min. Samples have been analyzed by denaturing urea/polyacrylamide gel electrophoresis in TBE (48 mM Tris, 45.5 mM Boric Acid, 1 mM EDTA).

### **Kinetics of Religation Using Oligonucleotide Substrate**

20 nM CL14/CP25 were incubated with an excess of enzyme for 60 min at 23°C followed by 30 min at 37°C in 20 mM Tris pH 7.5, 0.1 mM Na<sub>2</sub>EDTA, 10 mM MgCl<sub>2</sub>, 50 µg/ml acetylated BSA, and 150 mM KCl. The cleavable complex formed was pre-incubated for 10 min with DMSO, as a control, and ERYC, respectively. 5 µl sample of the reaction mixture was removed before addition R11 and used as the zero time point. Religation reactions were initiated by adding a 200-fold molar excess of R11 oligonucleotide (5'-AGAAAATTTT-3') over the duplex CL14/CP25. At 37°C a various time points, 5 µl aliquots were removed and the reaction stopped with 0.5% (v/v) SDS. After ethanol precipitation, samples were resuspended in 5 µl of 1 mg/ml trypsin and incubated at 37°C for 30 min. Samples were analyzed by denaturing urea/polyacrylamide gel electrophoresis in TBE (48 mM Tris, 45.5 mM Boric Acid, 1 mM EDTA).

### Electrophoretic mobility shift assay (EMSA)

The double stranded 25 bp oligonucleotide CL25/CP25 was prepared as described for the cleavage/equilibrium assay. The reactions were carried out using the catalytically inactive mutant enzyme Tyr723Phe. Two different concentrations of mutant enzyme were incubated in standard reaction conditions [20 mM Tris pH 7.5, 0.1 mM Na<sub>2</sub>EDTA, 10 mM MgCl<sub>2</sub>, 50 µg/ml acetylated BSA, 150 mM KCl] in presence of 1% (v/v) DMSO or 100 µM ERYC at 37°C for 10' in a final volume of 30 µl. After pre-incubation, DNA substrate was added and the binding reactions were performed for 10' at 37°C. Reactions were stopped by addition of 7 µl dye (0.125 % (w/v) bromophenol blue and 40 % (v/v) glycerol). Samples were loaded on 6% (v/v) native polyacrilamide gels and electrophoresed at 70 Volts in TBE (12 mM Tris, 11.4 mM Boric Acid, 0.2 mM EDTA). Products were visualized by phosphorimaging.

### Molecular Docking procedure

Molecular Docking is a computational technique that predicts the putative binding site of a ligand on a receptor, taking into account both geometrical and electrostatic match contributions. The Docking has been conducted with the Autodock 4 program, using the AutodockTools suite v. 4 to prepare the structures of ligand and receptor [19]. The docking runs with the free enzyme have been carried out using the structure of the protein coming from the crystal structure 1a36 [5], and 1ej9 [20], where missing residues were reconstructed with a procedure already described [21,22], once the DNA substrate was eliminated. The docking with the binary complex was carried out using the 3D coordinates coming from the ternary complex crystal structure 1k4t [23], after elimination of TPT. Partial atomic charges of ERYC have been calculated using Restrained Electrostatic Potential fitting (RESP) method [24]. Geometric optimization has been carried out with Gaussian03 [25] at B3LYP/6-31G\* level of theory. The water solvation effect has been taken in account by means of the COSMO variant of the polarizable continuum model [26]. For the docking experiment 250 runs have been performed, using the Lamarckian Genetic Algorithm



[27]. The simulative box (38 x 48 x 38 Å) was built to contain the inner cavity of the protein, dedicated to accommodate the DNA, and the residues lateral chains protruding into it, and centered on its geometric center. The analysis of the contacts between the ligand and the receptor in all the resulting structures was done using a modified version of the program `g_mindist` from the Gromacs 3.3.3 package [28], taking a threshold value of 3.5 Å. Images were obtained with the UCSF Chimera [29] and VMD visualization packages [30].

## RESULTS

### ERYC inhibits the catalytic activity of human Top1

The inhibitory effect of ERYC on human Top1 activity has been assessed by a plasmid relaxation assay (Figure 2A). Native protein has been incubated with a supercoiled plasmid in absence or presence of increasing concentration of compound and the relaxation activity has been monitored after 1 hour. The data indicate that ERYC inhibits the relaxation activity of Top1 in a dose dependent manner and also as a function of the pre-incubation with the enzyme (Figure 2A). In fact simultaneous addition of enzyme, ERYC and DNA determines an inhibition of the relaxation activity that starts at 8  $\mu\text{M}$  ERYC (Figure 2A, lane 4) and is maximal at a drug concentration of 20-25  $\mu\text{M}$  (Figure 2A, lanes 7 and 8), although a complete inhibition is never achieved under these conditions. The assay, carried out after pre-incubating the enzyme with increasing concentration of ERYC before the addition of DNA, shows a greater inhibitory effect on Top1 activity, with a full inhibition already at 12  $\mu\text{M}$  concentration (Figure 2A, compare lanes 5 and 13). As control it is shown that ERYC does not affect the electrophoretic mobility of DNA in the absence of Top1 (Figure 2A, lane 17). Since ERYC is dissolved in DMSO, an assay of the enzyme activity in presence of an identical concentration of DMSO without ERYC has been also carried out, to show that it does not affect the relaxation activity of Top1 (Figure 2A, lanes 1 and 9). This result indicates that, upon incubation, ERYC is an efficient inhibitor of the relaxation more efficient than CPT when used at the same concentration. In fact when the relaxation is carried out after 1 hour a slight inhibitory effect of CPT is observed only at 20/25  $\mu\text{M}$  concentration (Figure 1 supplementary materials). This could be in part expected since CPT is known to be a reversible inhibitor [31]. The assay has then been carried out as a function of time for both CPT and ERYC choosing a concentration of 20  $\mu\text{M}$  for both drugs. This is illustrated in figure 2B where it is shown that the effect of ERYC occurs after 30 sec and it is maintained over time (lanes 9-16), whilst that of CPT occurs again after 30 sec, (lane 17) but it is nearly abolished after 8 min (lanes 22-23), indicating that the binding of ERYC and CPT is irreversible and reversible, respectively. The relaxation assay in presence of only DMSO is also reported to show that the solvent has no effect (Fig. 2B lanes 1-8).

The complete inhibition of the pre-incubated ERYC-enzyme also remains after a 3-fold or 9-fold dilution, confirming that the inhibitory effect is irreversible as shown in figure 2C (lanes 4-6), where it is also shown that the enzyme pre-incubated with DMSO, as a control, and diluted maintains its activity (lanes 1-3). As a control it has been verified that the gel electrophoresis of DNA in presence of ERYC (Figure 2C lane 7) is identical to that of DNA alone (data not shown).

### Effects of ERYC on cleavage/religation equilibrium

To investigate the effect of ERYC on the cleavage/religation equilibrium, the stability

of the covalent DNA–enzyme complex has been analyzed using the 25 mer full duplex oligonucleotides substrate CL25 (5'-GAAAAAGACTTAGAGAAAAATTTT-3')/CP25 in the presence of ERYC, CPT or ERYC and CPT together (Figure 3). When the enzyme is incubated with DMSO (Figure 3, lane 1), a very small level of cleavage of the labeled DNA strand is detected at the preferred DNA cleavage site, as indicated by the asterisk in Figure 3. When Top1 is exposed to CPT, a dramatic increase in cleaved DNA fragments is observed (lane 2) indicating that the equilibrium is shifted toward cleavage since the drug reversibly binds to the covalent intermediate DNA-enzyme, stabilizing the cleavable complex and reducing the religation rate [32]. When the protein is incubated with ERYC the band of the cleavable complex is not observed at all (lane 3). Pre-incubation of ERYC with the enzyme before addition of substrate and CPT (lane 5) does not permit the stabilization of the cleavable complex by CPT, while pre-incubation of CPT with the enzyme before addition of substrate and ERYC (lane 4) does not alter the inhibition mechanism of CPT. The data can be interpreted either considering that ERYC inhibits the cleavage or that induces a faster religation, in both cases not permitting the cleavable complex stabilization.

### **Cleavage and religation assays in the absence and presence of ERYC**

The cleavage of the enzyme as a function of ERYC concentrations has been followed using a suicide cleavage substrate. In detail, a 5' end radiolabeled oligonucleotide CL14 (5'-GAAAAAAGAC\*TT'AG-3') has been annealed to the CP25 (5'-TAAAAATTTTCTAAGTCTTTTTC-3') complementary strand, to produce a duplex with an 11-base 5' single-strand extension. The enzyme cuts preferentially at the site indicated by the arrow and to a lower extent at the site indicated by the asterisk. In both cases the religation step is precluded because the AG-3' or TTAG-3' oligonucleotides are too short to be religated, leaving the enzyme covalently attached to the 12 or 10 oligonucleotide 3' end. The presence of the cleaved DNA fragments has been monitored in presence of different pre-incubated concentrations of ERYC in a denaturing polyacrylamide gel (Figure 4). The data indicate that increasing ERYC concentrations decreases the percentage of protein able to cleave the substrate and that at 30  $\mu$ M the enzyme is fully inhibited. This behavior precludes to carry out a study of the effect of ERYC on the cleavage rate, since at any concentrations lower than 30  $\mu$ M there are two protein populations: a fully inhibited one having a strongly bound ERYC, and a fully unbound active protein.

The DNA religation step has been studied by testing the ability of the wild type protein to religate the R11 (5'-AGAAAAATTTT-3') oligonucleotide added to the cleaved suicide substrate previously incubated with an excess of enzyme. The religation has been followed in the absence of the drug or prior incubation of the cleavable suicide complex with ERYC. Aliquots have been removed at different times, the reaction stopped by addition of SDS and the products analyzed by polyacrylamide gel electrophoresis (Figure 5). The figure clearly shows that in the

absence of the drug the wild type protein religates the R11 oligonucleotide in a time dependent manner, while the presence of the drug fully inhibits the religation step confirming that also in this case ERYC irreversibly binds to the protein-DNA-complex.

### **Electrophoretic mobility shift assay**

The lack of any cleavage activity in the presence of ERYC could be due to an effect of the drug in preventing the binding of the protein to the DNA or to an inhibition of the catalytic reaction. In order to clarify this point an electrophoretic mobility shift assay (EMSA) has been performed to explore whether ERYC prevents binding of Top1 to DNA. To this purpose the inactive human recombinant mutant (Tyr723Phe), in which the tyrosine 723 is substituted by a phenylalanine, has been pre-incubated with 100  $\mu$ M ERYC for 10 minutes, a 25 base pairs double stranded DNA has then been added and the samples have been resolved into a native polyacrylamide gel. In the absence of protein (Figure 6, lanes 1, 3, 5, 7) no DNA shift can be observed. In the presence of the Tyr723Phe mutant either in absence (lane 2) or in presence of ERYC (lane 4) two slowly migrating Top1-DNA complexes are formed, corresponding to DNA bound to a full protein (Top1-DNA-complex 1) and to DNA bound to a partially degraded form of the protein (Top1-DNA complex 2). The intensity of the band corresponding to the Top1-DNA complex 1 increases doubling the protein concentrations (compare lanes 2 and 4 with lanes 6 and 8) being 17 for the Top1-DNA-complex 1 in lanes 2 and 4 and 35 for the Top1-DNA-complex1 in lanes 6 and 8, demonstrating that ERYC does not prevent the Top1-DNA complex formation.

### **Protein-ligand interaction**

The interaction between Top1 and ERYC has been explored by carrying out 250 runs of Molecular Docking on the structure of the protein in absence of the DNA substrate. In more than 70% of the results, ERYC is interacting with the same protein region (site I), near the loop connecting subdomain III with the linker domain (Figure 7A). In about 30% of the complexes another binding region is identified (site II) in proximity of the segment connecting the cat and cap domains, formed by helices  $\alpha$ 8 and  $\alpha$ 9 (data not shown). The complexes belonging to the first binding site are characterized by a free energy value ranging from -4.6 to -6.6 Kcal/mol that are in average 1 Kcal/mol lower than that found in the second site, confirming site I as the preferential binding site.

Analysis of the contacts established between the protein and the ligand in the preferential binding site indicates that ERYC is in close contact with two residues of the catalytic pentad, Arg488 and His632, through the drug prenilic substituent in position 8 (Figure 7B), providing a molecular explanation for the inhibitory effect of the drug. Indeed, these two residues are fundamental during the interaction with the scissile base, establishing contacts with the bridging and nonbridging oxygens during

the stabilization of the transition state [5,33,34]. Moreover, Arg488 has been proposed to accept a proton from Tyr723, either directly or via a water molecule, during the nucleophilic attack [34-36]. Binding of the drug in site I does not produce a steric hindrance, such as to impede the DNA binding. In fact, the DNA substrate can be accommodated also in presence of the drug (data not shown), in agreement with the experimental findings and confirming that the inhibition effect is not due to the DNA binding prevention, but to an effect on the enzyme catalytic site.

A docking experiment has been also carried out between ERYC and the protein-DNA binary complex using the ternary complex X-ray structure [23] where the topotecan drug has been eliminated. 250 docking runs have been carried out either for ERYC, TPT or CPT. In the case of ERYC and TPT, two main binding sites are identified (Figure 8A and B), one with the drug intercalating between the base pairs in position -1/+1, in a position similar to the one found in the X-ray structure of the ternary complex, the other one in the same site identified for the free enzyme (site I) (Figures 7 and 8A and B). The binding energy for ERYC in these two sites is comparable and of the order of -7 Kcal/mol. The binding energy for the two sites is comparable for topotecan as well but it is less favorable than ERYC by about 3 Kcal/mol suggesting that ERYC can be a suitable scaffold to be used as a Top1 poison. Interestingly, in the case of CPT in all the 250 docked structures the drug intercalates between the +1/-1 bases, and the other site is not visible at all (Fig. 8C), suggesting that CPT is highly specific as confirmed by the binding energy that varies between -7.7 and -10.7 Kcal/mol, for all the 250 complexes.

## DISCUSSION

The results here presented indicate that ERYC inhibits both cleavage and religation reactions catalyzed by human topoisomerase IB. The drug is then able to interact with the enzyme alone or with the DNA-enzyme cleavable complex, in both cases inhibiting the enzyme active site. The drug is acting with a mechanism completely different to the drugs belonging to the CPT family drugs, likely the drugs better characterized for this class of enzymes [37]. CPT is classified as a poison, since converts topoisomerase into a cell poison, reversibly binding at the interface of the DNA-topoisomerase cleavable complex trapping it long enough to permit collision with the replication fork [38]. The mechanism of CPT can be easily understood observing figure 3 where the band of the cleavable complex, stabilized by the drug, appears (lane 2). On the other hand such a band is not observed in presence of ERYC (lane 3) or even after addition of CPT to an enzyme pre-incubated with ERYC suggesting that ERYC does not permit the cleavage of DNA because of a direct interaction between the drug and the enzyme. This is one of the differences between ERYC and CPT, ERYC is able to interact with the enzyme alone binding in proximity of the active site and inhibiting the cleavage process, whilst CPT does not bind to the free enzyme and only binds to the DNA-enzyme cleavable complex. Another interesting difference concerns the reversibility: CPT binds in a reversible way whilst binding of ERYC is irreversible. The irreversibility of the ERYC binding can be observed either monitoring the relaxation (Figure 2), the cleavage (Figure 4) or the religation (Figure 5) reactions. Complete inhibition of the relaxation process can in fact be achieved only pre-incubating the enzyme with ERYC (Figure 2 A). Moreover the inhibition remains also after a 9-fold dilution, at a concentration where the enzyme, in absence of the drug, is active (Figure 2C), confirming that the ERYC binding is irreversible. The same indication is obtained when the drug is incubated with the cleavable suicide complex (Figure 5): in absence of the drug the enzyme religates in a time dependent manner, whilst in presence of the drug the religation step is constantly inhibited at any time. It is likely that binding of the drug induces some enzyme conformational change that renders the binding irreversible.

The docking of the ERYC molecule to Top1 provides a molecular explanation for the inhibition effect although cannot provide a clear information for the irreversibility. For the enzyme alone the preferential drug binding site is found near the two active site residues Arg488 and His632 (Figure 7), both implicated in the reaction catalysis, possibly inhibiting their action. It is interesting to notice that once the molecule is bound to the enzyme, there is still space to accommodate the DNA substrate into the cavity (data not shown) in perfect agreement with the experimental result that indicate that the presence of ERYC does not prevent the DNA binding (Figure 6).

Docking of the drug with the DNA-enzyme cleavable complex indicates the occurrence of two binding sites, one intercalating the -1/+1 cleaved base pair, the other one identical to the binding site found in the free enzyme (Figures 7A and 8A).

The docking procedure can then explain the inhibitory property of the drug but not its irreversibility. However, it is also interesting to remark that the binding energy indicates that ERYC binds the cleavable complex even more efficiently than TPT suggesting that it can be a potential scaffold to be used for therapeutic purpose.

The data here presented indicate that ERYC is *in vitro* a catalytic inhibitor of human topoisomerase I efficiently acting both on the cleavage and on the religation reaction. However, these data cannot permit to discuss how much this inhibition contributes to the cytotoxicity of the drug itself. In fact the primary mechanism of cell killing by Top1 poison, as CPT, is S-phase-specific [38] through potentially lethal collisions between advancing replication forks and Topo1 cleavable complexes. ERYC has been found to induce a dose-dependent cytotoxicity unrelated to genotype status of the cell lines and without apparent cell cycle check-point arrest [9]. It is then likely that in cells Top1 is not the only target of ERYC and that the observed apoptosis is due to the interaction of multiple molecular targets.

In conclusion we have characterized the *in vitro* interaction of ERYC with Top1 demonstrating that this drug has unique properties being able to act either as a cleavage or religation inhibitor, suggesting that appropriate chemical modifications can be introduced to confer to the drug the ability to act on a single catalytic step process.

### **AUTHOR CONTRIBUTION**

All experiments were performed by Cinzia Tesauro under the supervision of Paola Fiorani and Alessandro Desideri, the Molecular Docking experiments were performed by Ilda D'Annessa under the supervision of Giovanni Chillemi. Figures were prepared by Paola Fiorani and Ilda D'Annessa. ERYC was kindly provided by Gino Turchi.

### **ACKNOWLEDGMENTS**

The authors would like to thank the CASPUR-Computational Centre for the computer architecture used in this work. We also thank A. Coletta for the charge analysis on the structure of ERYC and also B. Arnò and L. Zuccaro for some help in the experiments.

### **FUNDING**

This work was partly supported by the AIRC project to A.D. 'Characterization of human topoisomerase I mutants resistant to camptothecin and its derivatives'.

Accepted Manuscript



## REFERENCES

1. Champoux, J. (2001) DNA topoisomerases: structure, function, and mechanism. *Annu. Rev. Biochem.*, **70**, 369-413.
2. Wang, J.C. (1996) DNA topoisomerases. *Ann. Rev. Biochem.*, **65**, 635-692.
3. Stewart, L., Ireton, G.C., Parker, L.H., Madden, K.R. and Champoux, J.J. (1996) Biochemical and biophysical analysis of recombinant forms of human DNA topoisomerase I. *J. Biol. Chem.*, **271**, 7593-7601.
4. Redinbo, M.R., Stewart, L., Kuhn, P., Champoux, J.J. and Hol, W.G.J. (1998) Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. *Science*, **279**, 1504-1513.
5. Stewart, L., Redinbo, M.R., Qiu, X., Hol, W.G.J. and Champoux, J.J. (1998) A model for the mechanism of human topoisomerase I. *Science*, **279**, 1534-1541.
6. Burden, D.A. and Osheroff, N. (1998) Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. *Biochim. Biophys. Acta.*, **1400**, 139-154.
7. Holden, J.A. (2001) DNA topoisomerases as anticancer drug targets: from the laboratory to the clinic. *Curr. Med. Chem. Anticancer Agents.*, **1**, 1-25.
8. Pommier, Y. (2009) DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition. *Chem. Rev.*, in the press.
9. Maurich, T., Iorio, M., Chimenti, D. and Turchi, G. (2006) Erybraedin C and bitucarpin A, two structurally related pterocarpanes purified from *Bituminaria bituminosa*, induced apoptosis in human colon adenocarcinoma cell lines MMR- and p53-proficient and -deficient in a dose-, time-, and structure-dependent fashion. *Chem. Biol. Interact.*, **159**, 104-116.
10. Mitscher, L.A., Okwute, S.K., Gollapudi, S.R., Drake, S. and Avona, E. (1988) Antimicrobial pterocarpanes of Nigerian *Erythrina mildbraedii*. *Phytochemistry*, **27**, 3449-3452.
11. Pistelli, L., Noccioli, C., Appendino, G., Bianchi F., Sterner, O. and Ballero, M. (2003) Pterocarpanes from *Bituminaria morisiana* and *Bituminaria bituminosa*. *Phytochemistry*, **64**, 595-598.
12. Rosa, A., Deiana, M., Corona, G., Atzeri, A., Incani, A., Appendino G. and Dessì, M.A. (2005) Antioxidant properties of extracts and compounds from *Psoralea morisiana*. *Eur. J. Lipid Sci. Technol.*, **107**, 521-529.
13. Turchi, G., Alagona, G. and Lubrano, V. (2009) Protective activity of plicatinB against human LDL oxidation induced in metal ion-dependent and-independent processes. Experimental and theoretical studies. *Phytomedicine.*, in the press.
14. Maurich, T., Pistelli, L. and Turchi, G. (2004) Anti-clastogenic activity of two structurally related pterocarpanes purified from *Bituminaria bituminosa* in cultured human lymphocytes. *Mutat. Res.*, **561**, 75-81.
15. Bjornsti, M.-A., Benedetti, P., Viglianti, G.A. and Wang, J.C. (1989) Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. *Cancer Res.*, **49**, 6318-6323.
16. Kauh, E.A. and Bjornsti, M.-A. (1995) CT1 mutants suppress the camptothecin sensitivity of yeast cells expressing wild-type DNA topoisomerase I. *Proc. Natl. Acad. Sci.*, **92**, 6299-6303.
17. Fiorani, P., Amatruda, J.F., Silvestri, A., Butler, R.H., Bjornsti, M.A. and Benedetti, P. (1999) Domain Interactions Affecting Human DNA Topoisomerase I Catalysis and Camptothecin Sensitivity. *Mol. Pharmacol.*, **56**, 1105-1115.
18. Yang, Z. and Champoux, J.J. (2002) Reconstitution of enzymatic activity by the association

- of the cap and catalytic domains of human topoisomerase I. *J Biol Chem.*, **277**, 30815-30823.
19. Morris, G.M., Huey, R., Lindstrom, W., Sanner, M.F., Belew, R.K., Goodsell, D.S. and Olson, A.J. (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. *J. Comput. Chem.*, in the press.
  20. Redinbo, M.R., Champoux, J.J. and Hol, W.G. (2000) Novel insights into catalytic mechanism from a crystal structure of human topoisomerase I in complex with DNA. *Biochemistry*, **39**, 6832-6840.
  21. Chillemi, G., Bruselles, A., Fiorani, P., Bueno, S. and Desideri, A. (2007) The open state of human topoisomerase I as probed by molecular dynamics simulation. *Nucleic Acids Res.*, **35**, 3032-3038.
  22. Chillemi, G., D'Annessa, I., Fiorani, P., Losasso, C., Benedetti, P. and Desideri, A. (2008) Thr729 in human topoisomerase I modulates anti-cancer drug resistance by altering protein domain communications as suggested by molecular dynamics simulations. *Nucleic Acids Res.*, **36**, 5645-5651.
  23. Staker, B.L., Hjerrild, K., Feese, M.D., Behnke, C.A., Burgin, A.B. and Stewart, L. (2002) The mechanism of topoisomerase I poisoning by a camptothecin analog. *Proc. Natl. Acad. Sci.*, **99**, 15387-15392.
  24. Bayly, C.I., Cieplak, P., Cornell, W. D. and Kollman, P. A. (1993) A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: The resp model. *J. Phys. Chem.*, **97**, 10269-10280.
  25. Frisch et al. (2004) Gaussian 03, Revision C.02. Gaussian, Inc., Wallingford CT.
  26. Cossi, M., Rega, N., Scalmani, G. and Barone, V. (2003) Energies, structures, and electronic properties of molecules in solution with the c-pcm solvation model. *J. Comput. Chem.*, **24**, 669-681.
  27. Morris, G.M., Goodsell, D.S., Halliday, R.S., Huey, R., Hart, W.E., Belew, R.K. and Olson, A.J. (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. *J. Comput. Chem.*, **19**, 1639-1662.
  28. Lindahl, E., Hess, B. and van der Spoel, D. (2001) GROMACS 3.0: A package for molecular simulation and trajectory analysis. *J. Mol. Mod.*, **7**, 306-317.
  29. Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C. and Ferrin, T.E. (2004) UCSF Chimera - A Visualization System for Exploratory Research and Analysis. *J. Comput. Chem.*, **25**, 1605-1612.
  30. Humphrey, W., Dalke, A. and Schulten, K. (1996) VMD: visual molecular dynamics. *J. Mol. Graph.*, **33**, 27-28.
  31. Liu, L.F. (1989) DNA Topoisomerase Poisons as Antitumor Drugs. *Ann. Rev. Biochem.*, **58**, 351-375.
  32. Fiorani, P., Bruselles, A., Falconi, M., Chillemi, G., Desideri, A. and Benedetti, P. (2003) Single mutation in the linker domain confers protein flexibility and camptothecin resistance to human topoisomerase I. *J. Biol. Chem.*, **278**, 43268-43275.
  33. Yang, Z. and Champoux, J.J. (2001) The role of histidine 632 in catalysis by human topoisomerase I. *J. Biol. Chem.*, **276**, 677-685.
  34. Davies, D.R., Mushtaq, A., Interthal, H., Champoux, J.J. and Hol, W.G. (2006) The structure of the transition state of the heterodimeric topoisomerase I of *Leishmania donovani* as a vanadate complex with nicked DNA. *J. Mol. Biol.*, **357**, 1202-1210.
  35. Krogh, B.O. and Shuman, S. (2000) Catalytic mechanism of DNA topoisomerase IB. *Mol. Cell.*, **5**, 1035-1041.
  36. Krogh, B.O. and Shuman, S. (2002) Proton relay mechanism of general acid catalysis by DNA topoisomerase IB. *J. Biol. Chem.*, **277**, 5711-5714.

37. Pommier, Y., Pourquier, P., Fan, Y. and Strumberg, D. (1998) Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. *Biochim. Biophys. Acta.*, **1400**, 83-106.
38. Liu, L.F. (1990) Anticancer drugs that convert DNA topoisomerases into DNA damaging agents. *DNA Topology and Its Biological Effects* (Cozzarelli, N. R., Wang, J., ed.), pp. 371-389, Cold Spring Harbor Lab Press.

Accepted Manuscript

THIS IS NOT THE VERSION OF RECORD - see doi:10.1042/BJ20091127

## FIGURE LEGENDS

**Figure 1. Molecular structure of ERYC.** Ball and stick representation of the ERYC molecule with the C, O and H atoms colored grey, black and white, respectively. The numeration of the atoms follows that found in Maurich et al., 2004 [14].

**Figure 2. Relaxation of supercoiled DNA.** (A) Relaxation of negative supercoiled plasmid DNA by Top1 with increasing concentrations of ERYC (lanes 2–8) or after pre-incubation for 10 min at 37 °C with increasing concentration of ERYC (lanes 10–16). Lanes 1 and 9 no drug added, lane 17 no protein added. (B) Relaxation of negative supercoiled in a time course experiment for DMSO (lanes 1–8), 20  $\mu$ M ERYC (lanes 9–16) and 20  $\mu$ M CPT (lanes 17–24), lane 25 no protein added (C). Relaxation assay of Top1 preincubated with DMSO or ERYC (100  $\mu$ M) for 10 min and then diluted 3- or 9-fold. Lane 7 no protein added. The reaction products are resolved in an agarose gel and visualized with ethidium bromide. The bands indicated by the arrows correspond to (Dimer), dimer supercoiled plasmid DNA, (NC), nicked supercoiled plasmid DNA, (SC), supercoiled plasmid DNA.

**Figure 3. Cleavage-religation equilibrium.** Gel electrophoresis of the products coming from the incubation of Top1 with the [ $\gamma$ -<sup>32</sup>P] end-labelled duplex DNA, shown at the top of the figure. The arrow on the DNA sequence indicates the CL1 preferred cleavage site. The duplex is incubated with the enzyme alone (lane 1) in presence of CPT (lane 2), in presence of ERYC (lane 3) after preincubation with CPT and then addition of ERYC (lane 4), after preincubation with ERYC and then addition of CPT (lane 5). In the last lane the enzyme has not been added. The asterisk indicates the band corresponding to the CL1 site.

**Figure 4. Suicide cleavage experiment in presence of different concentrations of ERYC.** A ERYC dose dependent suicide cleavage reaction was carried out with the substrate described on the top of the figure. Different concentrations of ERYC were pre-incubated with the protein for 10 min at 37 °C and then incubated with the substrate for 30 min. CL1 represents the DNA fragment cleaved at the preferred site. Lane C, no protein added. The arrow and the asterisk indicate the first and the second cleavage site, respectively.

**Figure 5. Religation experiment in the absence and presence of ERYC.** Time course (0.5–60 min) of the religation experiment between the R11 substrate and the wild type-covalent complexes described on the top of the figure, in the absence or presence of 100  $\mu$ M ERYC. CL1 represents the DNA fragment cleaved at the preferred site. Religation represents the religated product.

**Figure 6. Electrophoretic mobility shift.** Electrophoretic mobility shift of the [ $\gamma$ -

<sup>32</sup>P] end-labelled CL25/CP25 DNA substrate alone (lane 1) in presence of the inactive Tyr723Phe mutant (lane 2); of ERYC (lane 3); of both the drug and the mutant (lane 4). Lanes 6 and 8 represent the same experiment reported in lanes 2 and 4 but with twice the enzyme concentration than in lanes 2 and 4. Top1-DNA complexes 1 indicates the DNA bound to a fully Top1 protein, Top1-DNA complexes 2 indicates the DNA bound to a degraded form of Top1 protein.

**Figure 7. Top1-ERYC binding pocket.** (A) Ribbon representation of the protein with subdomains I, II and III colored in yellow, blue and red respectively and the linker and C-terminal domain colored in green and cyan, respectively. The best docked ERYC-TOP1 complex is represented in orange in ball and stick. (B) Zoom of the binding pocket: the lateral chains of the residues contacting the drug are represented in ball and stick and colored following the domain color code.

**Figure 8. Docking of Top1- DNA binary complex with ERYC, TPT or CPT.** Spread of the docked structure of ERYC (A), TPT (B) or CPT (C) in the binary complex coming from the 1k4t structure. The protein and DNA are represented in blue and cyan ribbon, respectively. ERYC (A), TPT (B) and CPT (C) are represented in orange, yellow and magenta licorice, respectively.




Figure 1




Figure 2

THIS IS NOT THE VERSION OF RECORD - see doi:10.1042/BJ20091127




Figure 3






Figure 4

THIS IS NOT THE VERSION OF RECORD - see doi:10.1042/BJ20091127

Accepted Manuscript




Figure 5

THIS IS NOT THE VERSION OF RECORD - see doi:10.1042/BJ20091127

Accepted Manuscript




Figure 6

THIS IS NOT THE VERSION OF RECORD - see doi:10.1042/BJ20091127

Accepted Manuscript




Figure 7




Figure 8